Full Text View
Tabular View
No Study Results Posted
Related Studies
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
This study has been completed.
Study NCT00471952   Information provided by Diamond Headache Clinic

First Received on May 8, 2007.   Last Updated on April 24, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Migraine With Aura
Migraine Without Aura
Additional conditions recognized in this trial
Headache
Migraine Disorders
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases
Neurologic Manifestations
Pain
Signs and Symptoms
Interventions listed in this trial
Maxalt 10mg MLT plus Caffeine 75mg
Maxalt 10mg MLT plus Placebo
Placebo + Placebo
Additional drug interventions recognized in this trial
Caffeine
Rizatriptan
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Stimulants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Serotonin Agents
Serotonin Receptor Agonists
Therapeutic Uses
Sponsors listed in this trial
Diamond Headache Clinic
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services